Adjuvants help boost the immune response to the antigen in the vaccine, and can also help with dose sparing, according to a ...

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...

As World War II loomed, he attempted to enlist in the U.S. Navy, but he was rejected when his record revealed that he was gay ...

Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. Novavax, Inc. (NASDAQ:NVAX ...

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...

MANILA, Dec 21 (Reuters) - The Philippines expects to receive 30 million doses of Novavax Inc's COVID-19 vaccine by July next year, its foreign minister said on Monday, boosting the country's effort ...

The FDA’s top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.

This year’s updated COVID-19 vaccines have been approved by the U.S. Food and Drug Administration for adults 65 and older and younger people with certain medical conditions that put them at a higher ...

The Food and Drug Administration has approved Novavax's Nuvaxovid 2025-2026 formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years through 64 years of age with at ...